Cargando…
A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective?
Despite community vaccination against coronavirus disease 2019 (COVID-19) and reduced mortality, there are still challenges in treatment options for the disease. Due to the continuous mutation of SARS-CoV-2 virus and the emergence of new strains, diversity in the use of existing antiviral drugs to c...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823263/ https://www.ncbi.nlm.nih.gov/pubmed/36609716 http://dx.doi.org/10.1007/s10787-022-01129-1 |
_version_ | 1784866117453348864 |
---|---|
author | Nabi-Afjadi, Mohsen Mohebi, Fatemeh Zalpoor, Hamidreza Aziziyan, Fatemeh Akbari, Abdullatif Moradi-Sardareh, Hemen Bahreini, Elham Moeini, Amir Mansour Effatpanah, Hossein |
author_facet | Nabi-Afjadi, Mohsen Mohebi, Fatemeh Zalpoor, Hamidreza Aziziyan, Fatemeh Akbari, Abdullatif Moradi-Sardareh, Hemen Bahreini, Elham Moeini, Amir Mansour Effatpanah, Hossein |
author_sort | Nabi-Afjadi, Mohsen |
collection | PubMed |
description | Despite community vaccination against coronavirus disease 2019 (COVID-19) and reduced mortality, there are still challenges in treatment options for the disease. Due to the continuous mutation of SARS-CoV-2 virus and the emergence of new strains, diversity in the use of existing antiviral drugs to combat the epidemic has become a crucial therapeutic chance. As a broad-spectrum antiparasitic and antiviral drug, ivermectin has traditionally been used to treat many types of disease, including DNA and RNA viral infections. Even so, based on currently available data, it is still controversial that ivermectin can be used as one of the effective antiviral agents to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or not. The aim of this study was to provide comprehensive information on ivermectin, including its safety and efficacy, as well as its adverse effects in the treatment of COVID-19. |
format | Online Article Text |
id | pubmed-9823263 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-98232632023-01-09 A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective? Nabi-Afjadi, Mohsen Mohebi, Fatemeh Zalpoor, Hamidreza Aziziyan, Fatemeh Akbari, Abdullatif Moradi-Sardareh, Hemen Bahreini, Elham Moeini, Amir Mansour Effatpanah, Hossein Inflammopharmacology Review Despite community vaccination against coronavirus disease 2019 (COVID-19) and reduced mortality, there are still challenges in treatment options for the disease. Due to the continuous mutation of SARS-CoV-2 virus and the emergence of new strains, diversity in the use of existing antiviral drugs to combat the epidemic has become a crucial therapeutic chance. As a broad-spectrum antiparasitic and antiviral drug, ivermectin has traditionally been used to treat many types of disease, including DNA and RNA viral infections. Even so, based on currently available data, it is still controversial that ivermectin can be used as one of the effective antiviral agents to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or not. The aim of this study was to provide comprehensive information on ivermectin, including its safety and efficacy, as well as its adverse effects in the treatment of COVID-19. Springer International Publishing 2023-01-07 2023 /pmc/articles/PMC9823263/ /pubmed/36609716 http://dx.doi.org/10.1007/s10787-022-01129-1 Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Nabi-Afjadi, Mohsen Mohebi, Fatemeh Zalpoor, Hamidreza Aziziyan, Fatemeh Akbari, Abdullatif Moradi-Sardareh, Hemen Bahreini, Elham Moeini, Amir Mansour Effatpanah, Hossein A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective? |
title | A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective? |
title_full | A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective? |
title_fullStr | A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective? |
title_full_unstemmed | A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective? |
title_short | A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective? |
title_sort | cellular and molecular biology-based update for ivermectin against covid-19: is it effective or non-effective? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823263/ https://www.ncbi.nlm.nih.gov/pubmed/36609716 http://dx.doi.org/10.1007/s10787-022-01129-1 |
work_keys_str_mv | AT nabiafjadimohsen acellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective AT mohebifatemeh acellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective AT zalpoorhamidreza acellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective AT aziziyanfatemeh acellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective AT akbariabdullatif acellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective AT moradisardarehhemen acellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective AT bahreinielham acellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective AT moeiniamirmansour acellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective AT effatpanahhossein acellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective AT nabiafjadimohsen cellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective AT mohebifatemeh cellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective AT zalpoorhamidreza cellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective AT aziziyanfatemeh cellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective AT akbariabdullatif cellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective AT moradisardarehhemen cellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective AT bahreinielham cellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective AT moeiniamirmansour cellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective AT effatpanahhossein cellularandmolecularbiologybasedupdateforivermectinagainstcovid19isiteffectiveornoneffective |